title: Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.
abstract: Immunotherapy strategies targeting glioma stem-like cells (GSCs) hold promise for improving outcomes in glioblastoma patients. We used the A2B5 monoclonal antibody to classify GSCs derived from the mouse GL261 glioma cell line, and A2B5+ GL261 cell lysate-pulsed dendritic cells (DCs) were used to treat mouse glioma. We found that such DCs elicited a stronger specific cytotoxic T lymphocyte response against A2B5+ GL261 cells than A2B5- GL261 cell lysate-pulsed DCs. The effect of A2B5+ GL261 cell lysate-pulsed DCs in vivo depended on when the vaccination was started. In the tumor cell adaptation phase, C57BL/6 mice had an immune response against GL261, and vaccination enhanced the immune response and prevented glioma formation in 37.5% of mice. In contrast, after glioma formation, the immune response against GL261 was decreased, and vaccination had no therapeutic effect. Our findings suggest that vaccination with A2B5+ GL261 cell lysate-pulsed DCs only has some glioma preventive effect.
authors.affiliation: Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Xu
authors.forename: Yu
authors.initials: Y
authors.lastname: Yao
authors.forename: Wei
authors.initials: W
authors.lastname: Hua
authors.forename: Zhebao
authors.initials: Z
authors.lastname: Wu
authors.forename: Ping
authors.initials: P
authors.lastname: Zhong
authors.forename: Ying
authors.initials: Y
authors.lastname: Mao
authors.forename: Liangfu
authors.initials: L
authors.lastname: Zhou
authors.forename: Feifei
authors.initials: F
authors.lastname: Luo
authors.forename: Yiwei
authors.initials: Y
authors.lastname: Chu
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology*; D004195:Disease Models, Animal; D005434:Flow Cytometry; D005732:Gangliosides / Q000378:metabolism*; D005910:Glioma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D008810:Mice, Inbred C57BL; D018709:Statistics, Nonparametric; D013602:T-Lymphocytes, Cytotoxic; D013997:Time Factors; D014020:Tissue Extracts / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
chemical_list: D019496:Cancer Vaccines; D005732:Gangliosides; D014020:Tissue Extracts; C062875:ganglioside A2B5